Czech National Bank Purchases 17,373 Shares of AbbVie Inc. $ABBV

Czech National Bank raised its position in AbbVie Inc. (NYSE:ABBV) by 3.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 466,032 shares of the company’s stock after purchasing an additional 17,373 shares during the period. AbbVie accounts for approximately 0.7% of Czech National Bank’s portfolio, making the stock its 19th largest position. Czech National Bank’s holdings in AbbVie were worth $106,484,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Norges Bank bought a new stake in AbbVie during the second quarter valued at $4,288,200,000. Legal & General Group Plc boosted its position in AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after acquiring an additional 493,420 shares during the last quarter. Wellington Management Group LLP grew its holdings in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares during the period. Finally, Amundi raised its position in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after acquiring an additional 1,414,621 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

Shares of ABBV opened at $206.85 on Thursday. The stock has a 50-day moving average of $222.17 and a 200-day moving average of $224.62. The company has a market cap of $365.74 billion, a PE ratio of 87.65, a P/E/G ratio of 0.71 and a beta of 0.34. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Insiders Place Their Bets

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ABBV. Morgan Stanley boosted their price objective on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Royal Bank Of Canada assumed coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. Piper Sandler increased their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, UBS Group reduced their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a multi‑year partnership with Major League Baseball to expand its “Striking Out Cancer” program nationally — a high‑profile marketing and corporate‑responsibility move that should boost brand visibility and patient/public engagement without near‑term material costs. AbbVie Named Official Pharmaceutical Partner of Major League Baseball
• Positive Sentiment: Analysts and value investors are re‑examining ABBV after recent share weakness; one write‑up frames the pullback as a potential buying opportunity based on long‑term fundamentals and pipeline prospects, which can attract bargain hunters. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?
• Positive Sentiment: AbbVie’s psychiatry pipeline expansion (acquisition of bretisilocin) keeps the company positioned in fast‑growing neuropsychiatric markets; the deal supports longer‑term revenue diversification beyond core immunology and oncology franchises. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Neutral Sentiment: Investor attention and search interest in ABBV have spiked, which can increase short‑term volatility but doesn’t signal direction on its own. Investors Heavily Search AbbVie Inc. (ABBV)
• Neutral Sentiment: Related sector financing (e.g., Gilgamesh Pharma’s Series A) signals investor appetite for neuropsychiatric assets but is peripheral to AbbVie’s near‑term earnings. Gilgamesh Pharma Closes Oversubscribed $60 Million Series A
• Negative Sentiment: Competitive dynamics: analysts highlight that rivals (notably Eli Lilly) are seeing explosive growth from obesity medicines, whereas AbbVie’s near‑term growth remains concentrated in Skyrizi and Rinvoq—this relative growth gap could limit upside and keep valuation under pressure. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.